4[1]Institute for Safe Medication Practices. Hospital survey shows much more needs to be done to protect pediatric patients from medication errors. ISMP Medication Safety Alert, 2000[Z]. Available at: http://www.ismp.org/MSAarticles/PedsSurvey.html
5[2]US Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Washington, DC: US Food and Drug Administration, 1997, Docket No,97N-0165[Z]. Available at: http://www.fda.gov/cder/guidance/pedrule.html
6[3]Nordenberg T. Pediatric drug studies. Protecting pint-sized Patients[Z]. FDA Consum,1999,33:23
7[4]Cote CJ. Adverse drug reactions and the package insert[J]. Commentary Acta Paediatr, 1999,88:925
8[5]Zenk KE. Challenges in providing pharmaceutical care to pediatric patients[J]. Am J Health-Sys Pharm,1994,51:688
9[6]Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on pediatric wards: a prospective study[J]. Acta Paediatr,1999,88:965
10[7]Choonara I, Gill A, Nunn A. Drug toxicity and surveillance in children[J]. Br Clin Pharmacol,1996,42:407
